Homocysteine and C-Reactive Protein Levels in Parkinson's Disease
Author Information
Author(s): Zhang Limin, Yan Junqiang, Xu Yunqi, Long Ling, Zhu Cansheng, Chen Xiaohong, Jiang Ying, Yang Lijuan, Bian Lianfang, Wang Qing
Primary Institution: The Third Affiliated Hospital of Sun Yat-Sen University
Hypothesis
The combination of homocysteine and C-reactive protein levels may predict the outcomes of patients with Parkinson's disease and vascular parkinsonism.
Conclusion
The combination of homocysteine and C-reactive protein may be used to assess the progression of Parkinson's disease and vascular parkinsonism.
Supporting Evidence
- 100% of patients with PD and VP presented with non-motor symptoms.
- Significant correlations were found between CRP and UPDRS III in PD patients.
- Hcy levels were significantly correlated with disease severity in PD patients.
Takeaway
Doctors looked at blood levels of two substances, homocysteine and C-reactive protein, to see if they could help understand how Parkinson's disease and related conditions get worse.
Methodology
A cross-sectional study measuring plasma homocysteine and C-reactive protein levels in patients with Parkinson's disease and vascular parkinsonism.
Potential Biases
Potential bias due to the exclusion of patients with moderate/severe cognitive impairment and those with other neurological disorders.
Limitations
The study had a small sample size and focused mainly on early-stage patients, which may limit the generalizability of the findings.
Participant Demographics
88 patients (43 with Parkinson's disease, 45 with vascular parkinsonism); mean ages 58.9 years for PD and 67.0 years for VP.
Statistical Information
P-Value
p=0.011 for CRP correlation with UPDRS III in PD patients.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website